<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795275</url>
  </required_header>
  <id_info>
    <org_study_id>07-0749</org_study_id>
    <nct_id>NCT00795275</nct_id>
  </id_info>
  <brief_title>Incretin Effect in People With Impaired Fasting Glucose</brief_title>
  <acronym>1651</acronym>
  <official_title>Exploring the Incretin Effect in People With IFG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of
      glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to
      abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the
      objective of the current study. The investigators hypothesized that defects in GLP-1 may
      explain the inappropriate basal EGP and diminished insulin secretion in IFG, and,
      furthermore, that by increasing circulating GLP-1 levels (using a new medicine called
      &quot;sitagliptin&quot;) the investigators could reverse these defects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline and change in endogenous glucose production</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline and change in insulin secretion</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion in response to oral vs. IV glucose</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and change in hormones, substrates and insulin action</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>IFG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>people with impaired fasting glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>people with normal glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Januvia (sitagliptin phosphate)</intervention_name>
    <description>Januvia 100 mg po qd x 28 days for all subjects after baseline measures made</description>
    <arm_group_label>IFG</arm_group_label>
    <arm_group_label>NGT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, sedentary, non-smokers, men and women 45-70 years old Subjects were placed
             into 1 of the 2 groups based on two 2-hour 75g oral glucose tolerance tests (2h OGTT),
             separated by one week: a control group with normal glucose tolerance (NGT; n=14;
             fasting glucose &lt;5.6 mmol/l and 2h OGTT &lt;7.8 mmol/l), or IFG (n=10; fasting glucose
             5.6-6.9 mmol/l, and 2h OGTT &lt;7.8 mmol/l).

        Exclusion Criteria:

          -  Subjects were excluded for: thyroid stimulating hormone &lt;50 or &gt;500 mU/l, fasting
             triglycerides &gt;10.3 mmol/l, creatinine &gt;130 Î¼mol/l, elevated liver function tests (&gt;2X
             normal), hematocrit &lt; 38%, or WBC&lt;3.0 x 103. Use of medications for lipid and/or
             glucose lowering also excluded enrollees. Women may not have used hormone replacement
             therapy in the past 1 year. Smokers. BMI &lt;25 or &gt;40 kg/m2. Diabetes or impaired
             glucose tolerance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh Perreault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>December 27, 2012</last_update_submitted>
  <last_update_submitted_qc>December 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-diabetes</keyword>
  <keyword>isotopes</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin action</keyword>
  <keyword>GLP-1</keyword>
  <keyword>simple obesity</keyword>
  <keyword>impaired fasting glucose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 23, 2013</submitted>
    <returned>February 27, 2013</returned>
    <submitted>August 7, 2015</submitted>
    <returned>September 4, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

